68Ga-NYM096

68Ga-NYM096 is a radiopharmaceutical diagnostic agent developed for positron emission tomography (PET) imaging. It consists of a small-molecule ligand, NYM096, which is a potent inhibitor of Fibroblast Activation Protein (FAP), conjugated to the radioisotope Gallium-68 (68Ga) via a DOTA chelator. FAP is a type II transmembrane serine protease that is significantly overexpressed on cancer-associated fibroblasts (CAFs) within the stroma of various epithelial tumors, including lung, pancreatic, and breast cancers, while remaining nearly undetectable in most healthy adult tissues. By targeting the tumor microenvironment rather than the tumor cells themselves, 68Ga-NYM096 provides high-contrast imaging with low background activity. It is primarily investigated for its utility in tumor staging, detection of metastases, and monitoring treatment response, often demonstrating superior sensitivity to 18F-FDG in specific malignancies such as gastric and hepatic cancers.

Other names

Gallium-68 NYM096Gallium68 NYM096Gallium 68 NYM096[68Ga]Ga-NYM09668Ga-DOTA-NYM096